Research on histone deacetylase as a target for anticancer therapy

Abstract

Abstract: The disequilibrium of histone acetylation and deacetylation may cause tumor. Histone deacetylases (HDACs) maintain the equilibrium between histone acetylation and deacetylation by catalyzing the deacetylation of histone. They are related to many regulation processes containing transcription of oncogene, cell proliferation and differentiation, apoptosis and so on. HDACs inhibitors have become the hot field of researches, more than ten different HDACs inhibitors are testing for the treatment of both hematological and solid malignancies and show obvious antitumor activity.

Key words: Neoplasms, Histone deacetylase, Histone deacetylase inhibitor

LI Nan, JIANG Da-Ming, LIU Shuang-Ping. Research on histone deacetylase as a target for anticancer therapy[J]. Journal of International Oncology, 2016, 43(2): 116-.

References

［1］ Yang R, Wu Y, Wang M, et al. HDAC9 promotes glioblastoma growth via TAZmediated EGFR pathway activation［J］. Oncotarget, 2015, 6(10): 76447656. ［2］ Damaskos C, Karatzas T, Nikolidakis L, et al. Histone deacetylase (HDAC) inhibitors: current evidence for therapeutic activities in pancreatic cancer［J］. Anticancer Res, 2015, 35(6): 31293135. ［3］ Koeneke E, Witt O, Oehme I. HDAC family members intertwined in the regulation of autophagy: a druggable vulnerability in aggressive tumor entities［J］. Cells, 2015, 4(2): 135168. DOI:10.3390/cells4020135. ［4］ Herr MJ, Longhurst CM, Baker B, et al. Tetraspanin CD9 modulates human lymphoma cellular proliferation via histone deacetylase activity［J］. Biochem Biophys Res Commun, 2014, 447(4): 616620. DOI:10.1016/j.bbrc.2014.04.046. ［5］ Ding G, Liu HD, Huang Q, et al. HDAC6 promotes hepatocellular carcinoma progression by inhibiting P53 transcriptional activity［J］. FEBS Lett, 2013, 587(7): 880886. DOI:10.1016/j.febslet.2013.02.001. ［6］ Seo J, Min SK, Park HR, et al. Expression of histone deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in invasive ductal carcinomas of the breast［J］. J Breast Cancer, 2014, 17(4): 323331. DOI:10.4048/jbc.2014.17.4.323. ［7］ Chen MC, Chen CH, Wang JC, et al. The HDAC inhibitor, MPT0E028, enhances erlotinibinduced cell death in EGFRTKIresistant NSCLC cells［J］. Cell Death Dis, 2013, 4: e810. DOI:10.1038/cddis.2013.330. ［8］ Liu J, Edagawa M, Goshima H, et al. Role of ATF3 in synergistic cancer cell killing by a combination of HDAC inhibitors and agonistic antiDR5 antibody through ER stress in human colon cancer cells［J］. Biochem Biophys Res Commun, 2014, 445(2): 320326. DOI:10.1016/j.bbrc.2014.01.184. ［9］ Zhao B, He T. Chidamide, a histone deacetylase inhibitor, functions as a tumor inhibitor by modulating the ratio of Bax/Bcl2 and P21 in pancreatic cancer［J］. Oncol Rep, 2015, 33(1): 304310. DOI:10.3892/or.2014.3595. ［10］ Jin JS, Tsao TY, Sun PC, et al. SAHA inhibits the growth of colon tumors by decreasing histone deacetylase and the expression of cyclin D1 and survivin［J］. Pathol Oncol Res, 2012, 18(3): 713720. DOI:10.1007/s1225301294997. ［11］ Noh EJ, Lim DS, Jeong G, et al. An HDAC inhibitor, trichostatin A, induces a delay at G2/M transition, slippage of spindle checkpoint, and cell death in a transcriptiondependent manner［J］. Biochem Biophys Res Commun, 2009, 378(3): 326331. DOI:10.1016/j.bbrc.2008.11.057. ［12］ Yang B, Yu D, Liu J, et al. Antitumor activity of SAHA, a novel histone deacetylase inhibitor, against murine B cell lymphoma A20 cells in vitro and in vivo［J］. Tumour Biol, 2015, 36(7): 50515061. DOI:10.1007/s1327701531561. ［13］ Bae HJ, Jung KH, Eun JW, et al. MicroRNA221 governs tumor suppressor HDAC6 to potentiate malignant progression of liver cancer［J］. J Hepatol, 2015, 63(2): 408419. DOI:10.1016/j.jhep.2015.03.019. ［14］ Qiao Z, Ren S, Li W, et al. Chidamide, a novel histone deacetylase inhibitor, synergistically enhances gemcitabine cytotoxicity in pancreatic cancer cells［J］. Biochem Biophys Res Commun, 2013, 434(1): 95101. DOI:10.1016/j.bbrc.2013.03.059. ［15］ Dong M, Ning ZQ, Xing PY, et al. Phase Ⅰ study of chidamide (CS055/HBI8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas［J］. Cancer Chemother Pharmacol, 2012, 69(6): 14131422. DOI:10.1007/s0028001218475. ［16］ Mahalingam D, Mita M, Sarantopoulos J, et al. Combined autophagy and HDAC inhibition: a phase Ⅰ safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors［J］. Autophagy, 2014, 10(8): 14031414. DOI:10.4161/auto.29231. ［17］ Prince HM, Dickinson M. Romidepsin for cutaneous Tcell lymphoma［J］. Clin Cancer Res, 2012, 18(13): 35093515. DOI:10.1158/10780432.CCR113144.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying. Research progress of habitat analysis in radiomics of malignant tumors [J]. Journal of International Oncology, 2024, 51(5): 292-297.